A recent study reveals that individuals who discontinue new GLP-1 drugs like Wegovy and Mounjaro tend to recover reduced body mass much more quickly than those who halt traditional diet and exercise regimens.
Findings released in a prominent medical journal demonstrates that while obese people often shed substantial amounts of their body weight while using the jabs, the mass returns at an estimated rate of 0.8 kg per month upon discontinuation.
"Users purchasing these medications need to be informed of the risk of rapid weight regain when the therapy ends," cautioned researcher Dr. Susan Jebb.
Such speed of regain implies a return to original mass within about a year and a half.
Comparing Treatments
The study, which looked at 37 of trials involving thousands of patients, contrasted the effects of these new drugs with older methods.
The team note that people who lose weight through diet and exercise typically see a slower creep back—approximately 0.1 kg a month—after stopping.
Explaining the Rapid Regain
Nutrition scientists suggest the mechanism of the drugs is key to understanding the amplified regain.
GLP-1 drugs copy a body's own chemical called GLP-1, which moderates feelings of fullness.
"Sustained high doses of GLP-1 levels several times higher than normal may cause the system to produce less of its endogenous GLP-1, and may also reduce responsiveness to its actions," said Dr. Adam Collins, a nutrition researcher.
"Stopping of this medication results in hunger is no longer kept in check, making binge eating a significant risk."
A Lifelong Disease?
Medical guidelines recommend the jabs for individuals with obesity-related medical conditions, alongside prescribed lifestyle changes.
Many experts argue that, given the significant potential of weight regain, the therapy should be considered life-long.
This view is echoed by pharmaceutical companies, who state that the results "underscore the persistent character of obesity," comparing it to managing diseases like hypertension.
User Experiences
Individuals who have discontinued the jabs describe a intense resurgence of cravings.
"It was like something flipping and you're instantly extremely hungry," described one woman.
This difficulty is compounded if users have not established lasting dietary or behavioural modifications during treatment.
Growing Use
Figures show that a significant number of adults in the UK have used these injections in the past year, with interest remaining high.
- Adoption is higher among women than men.
- The 40s and 50s demographic shows the highest level of interest.
- A large proportion access the medications through private prescriptions rather than public health services.
Ultimately, experts stress that while the jabs are powerful tools for weight loss, they are not a permanent solution and long-term success hinges on combined behavioural support.
